Nephrotic syndrome induced by cetuximab in a patient with metastatic colorectal cancer

Autor:	Mustafa Korkmaz, Engin Hendem, Melek Karakurt Eryılmaz, Aykut Demirkıran, Mustafa Karaağaç, Mehmet Artaç
Rok vydání:	2022
Předmět:	Male Nephrotic Syndrome Rectal Neoplasms Antibodies Monoclonal Cetuximab Antineoplastic Agents Middle Aged ErbB Receptors Proteinuria Oncology Colonic Neoplasms Humans Female Pharmacology (medical) Colorectal Neoplasms Protein Kinase Inhibitors
Zdroj:	Journal of Oncology Pharmacy Practice. 28:998-1002
ISSN:	1477-092X 1078-1552
Popis:	Introduction Cetuximab, an anti-EGFR monoclonal antibody, often cause skin toxicity, most commonly acneiform rash. We present a rare case of glomerulonephritis associated with cetuximab therapy. Case Report A 58-year-old male patient recently completed cetuximab-based chemotherapy for metastatic colorectal adenocarcinoma. He presented with acute renal failure, anasarca edema and nephrotic proteinuria. The amount of protein in the 24-h urine test was over 15.6 grams. Management & Outcome The patient showed a dramatic improvement in renal function shortly after terminated of cetuximab therapy without immunosuppressive therapy. Discussion Therefore, drugs targeting epidermal growth factor receptor (EGFR) monoclonal antibody were thought to trigger nephrotic syndrome by causing glomerular damage. As a result, physicians using EGFR monoclonal inhibitors should be very careful about renal functions and proteinuria in patients.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b8fe2810437908ac77d46ac33211844 https://doi.org/10.1177/10781552211073790 Zobrazit plný text záznamu